ESR1 and hepatocellular carcinoma: Additionally, dihydrotanshinone I target estrogen receptor α upregulates its expression in a concentration-dependent manner, leading to the downregulation of BRCA1 and resulting in DNA double-strand breaks and proliferation inhibition in HCC cells [67].